Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

Market Cap	9.64B -26.1%
Revenue (ttm)	1.94B +19.6%
Net Income	327.00M -19.1%
EPS	1.04 -20.9%
Shares Out	316.05M
PE Ratio	29.34
Forward PE	15.03
Dividend	0.64 (2.11%)
Ex-Dividend Date	n/a

Volume	1,803,786
Average Volume	2,770,221
Open	30.50
Previous Close	30.51
Day's Range	30.01 - 30.85
52-Week Range	28.18 - 50.86
Beta	0.39
RSI	44.73
Earnings Date	Apr 30, 2026

About SHA:688076

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 2,247
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688076

Financial Performance

In 2025, SHA:688076's revenue was 1.94 billion, an increase of 19.57% compared to the previous year's 1.62 billion. Earnings were 327.00 million, a decrease of -19.14%.